M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss

The current frontline symptomatic treatment for Alzheimer’s disease (AD) is whole-body upregulation of cholinergic transmission via inhibition of acetylcholinesterase. This approach leads to profound dose-related adverse effects. An alternative strategy is to selectively target muscarinic acetylchol...

Descripción completa

Detalles Bibliográficos
Autores principales: Bradley, Sophie J., Bourgognon, Julie-Myrtille, Sanger, Helen E., Verity, Nicholas, Mogg, Adrian J., White, David J., Butcher, Adrian J., Moreno, Julie A., Molloy, Colin, Macedo-Hatch, Timothy, Edwards, Jennifer M., Wess, Jurgen, Pawlak, Robert, Read, David J., Sexton, Patrick M., Broad, Lisa M., Steinert, Joern R., Mallucci, Giovanna R., Christopoulos, Arthur, Felder, Christian C., Tobin, Andrew B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5272187/
https://www.ncbi.nlm.nih.gov/pubmed/27991860
http://dx.doi.org/10.1172/JCI87526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5272187/
https://www.ncbi.nlm.nih.gov/pubmed/27991860
http://dx.doi.org/10.1172/JCI87526

Ejemplares similares